Bold Therapeutics Inc.

Jun 24, 2024

Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 'Metals in Medicine' Gordon Research Conference

Apr 05, 2024

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

Jan 22, 2024

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024

Oct 09, 2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

Aug 17, 2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

Jul 15, 2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

Jun 11, 2020

Bold Therapeutics Expands COVID-19 Consortium

May 27, 2020

Bold Therapeutics Executes Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

Apr 15, 2020

Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19

Mar 27, 2020

Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19